OncoMatch/Clinical Trials/NCT05995028
Universal 4SCAR7U Targeting CD7-positive Malignancies
Is NCT05995028 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Universal CD7-specific CAR gene-engineered T cells for t-cell acute lymphoblastic leukemia.
Treatment: Universal CD7-specific CAR gene-engineered T cells — The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells. The study also aims to learn more about the function of CD7 targeting CAR T cells and their persistence in patients of hematological malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Biomarker criteria
Required: CD7 expression (positive)
Performance status
KARNOFSKY 81–100
Karnofsky performance status (KPS) score is higher than 80
Demographics
Prior therapy
Cannot have received: gene therapy
Previous treatment with any gene therapy products
Lab requirements
Blood counts
hgb≥80g/l
Kidney function
creatinine ≤ 2.5 × upper limit of normal
Liver function
ast and alt ≤ 3 × upper limit of normal, total bilirubin ≤ 2.0mg/dl
Cardiac function
cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05995028 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy disqualifies patients from enrollment.
Does this trial require CD7?
Yes, CD7 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify